Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07203677 · ClinicalTrials.gov registry record
Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)
A clinical trial of Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 49,065
- Enrollment target
- 1
- Study location
NCT07203677: Completed study of Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease, sponsored by Brigham and Women's Hospital.
NCT07203677 is a study of Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 49,065 participants, above the 2,582-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (1800% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07203677, a study of Type 2 Diabetes Mellitus and Atherosclerotic Cardiovascular Disease, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 49,065 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
To evaluate the comparative effect of tirzepatide vs sitagliptin on the composite of myocardial infarction, stroke, or all-cause mortality in patients with type 2 diabetes and atherosclerotic cardiovascular disease when following the inclusion and exclusion criteria of the SURPASS-CVOT trial.
Conditions Studied
Interventions
- DRUG Initiation of tirzepatide
- DRUG Initiation of sitagliptin
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49,065 participants |
| Start Date | 2025-09-19 |
| Est. Completion | 2025-10-15 |
What the finished NCT07203677 record still lists
NCT07203677 is an observational study that tracks outcomes without assigning an intervention. Its 49,065 participants enrollment target places it among the larger protocols in the corpus, above the 2,582-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (1800% higher).
The record links to 2 conditions, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Initiation of tirzepatide is the first listed.
NCT07203677 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07203677 about?
NCT07203677 is a clinical study titled "Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)". Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...
What is the current status of trial NCT07203677?
This trial is currently completed. The enrollment target is 49,065 participants. The study started on 2025-09-19. Estimated completion is 2025-10-15.
What conditions does trial NCT07203677 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus, Atherosclerotic Cardiovascular Disease.
What interventions are being tested in trial NCT07203677?
The interventions under investigation include: Initiation of tirzepatide (DRUG), Initiation of sitagliptin (DRUG).
Who is sponsoring clinical trial NCT07203677?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07203677 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07203677's enrollment target sits among peer trials
49,065 4th of 130 higher than 127 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The PRECISION II Study: Evaluating the Accuracy of the LabPatch Glucose Sensing System
RECRUITING
-
A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
-
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
RECRUITING
-
Preventing Type 2 Diabetes in Black Emergent Adult
RECRUITING · NA
-
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
RECRUITING
-
A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00500123 · 50,000 participants
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
- NCT01885299 · 50,000 participants
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
- NCT03452774 · 50,000 participants
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- NCT04629586 · 50,000 participants
The T1D Exchange Registry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI